Recent Updates
Recently added Catalysts
LRMR Positive Sentiment Score: 70/100

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Wednesday, November 1, 2023 1 min read
Key Takeaway: Larimar Therapeutics, Inc. will present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York on November 7, 2023. The company's management team will participate in a fireside chat and one-on-one investor meetings. The event will also be accessible via webcast, with a replay available for 30 days on the company’s website. Larimar is focused on developing treatments for complex rare diseases, including Friedreich's ataxia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Larimar Therapeutics is actively engaging with investors at a significant conference.
  • The management team is participating in discussions about complex rare diseases.
  • The company is developing promising treatments, including a lead compound for Friedreich's ataxia.

Full Press Release Details

BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023.
Details on the fireside chat can be found below.
Date: Tuesday, November 7, 2023
Time: 1:10 – 1:40 PM ET
Webcast Link: https://guggenheim.metameetings.net/events/ini23
Following the conclusion of the fireside chat, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
jallaire@lifesciadvisors.com
Chief Financial Officer
mcelano@larimartx.com

Frequently Asked Questions

When is the Guggenheim Conference taking place?

The Guggenheim 5th Annual Conference is on November 6-7, 2023.

What time is Larimar's fireside chat?

Larimar's fireside chat is scheduled for November 7, 2023, 1:10 – 1:40 PM ET.

How can I access the fireside chat webcast?

You can access the webcast via this link: https://guggenheim.metameetings.net/events/ini23.

What disease is Larimar's lead compound CTI-1601 targeting?

CTI-1601 is being developed as a potential treatment for Friedreich's ataxia.

Where can I find more information about Larimar Therapeutics?

More information about Larimar can be found at https://larimartx.com.

Tags: LRMR Viatris Investor Conferences Healthcare Friedreich's ataxia Guggenheim Conference rare diseases biotechnology
Last updated: Nov 1, 2023